A phase II trial of sorafenib in metastatic melanoma with tissue correlates

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Ott, Patrick A ^a   Hamilton, Anne ^b,c   Min, Christina ^a   Safarzadeh Amiri, Sara ^a   Goldberg, Lauren ^a   Yoon, Joanne ^a   Yee, Herman ^a   Buckley, Michael ^a   Christos, Paul J ^d   Wright, John J ^e   Polsky, David ^a   Osman, Iman ^a   Liebes, Leonard ^a   Pavlick, Anna C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN D1; DNA; KI 67 ANTIGEN; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; BRAF PROTEIN, HUMAN; PYRIDINE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DNA SEQUENCE; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; FLUSHING; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTESTINE PERFORATION; MALE; MELANOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; PAIN; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RASH; SEQUENCE ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME; WILD TYPE; BIOSYNTHESIS; CLINICAL TRIAL; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CYCLIN D1; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION;

EID: 78650824497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015588     Document Type: Article

References (38)

1. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, et al. (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24: 4738-4745.
2. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, et al. (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17: 2745-2751.
3. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, et al. (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18: 158-166.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
5. Dong J, Phelps RG, Qiao R, Yao S, Benard O, et al. (2003) BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63: 3883-3885.
6. Gorden A, Osman I, Gai W, He D, Huang W, et al. (2003) Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 63: 3955-3957.
7. Sherr CJ (1996) Cancer cell cycles. Science 274: 1672-1677.
8. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA (2003) Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198-5202.
9. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, et al. (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23: 6292-6298.
10. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, et al. (2008) BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 6: 751-759.
11. Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, et al. (2006) Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 66: 999-1006.
12. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, et al. (2006) BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98: 326-334.
13. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.
14. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
15. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
16. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, et al. (2005) Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65: 2412-2421.
17. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, et al. (2006) Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95: 581-586.
18. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, et al. (2008) Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 26: 2178-2185.
19. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, et al. (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27: 2823-2830.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
21. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, et al. (2008) Metaanalysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26: 527-534.
22. Yancovitz M, Yoon J, Mikhail M, Gai W, Shapiro RL, et al. (2007) Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn 9: 178-183.
23. Albino AP, Juan G, Traganos F, Reinhart L, Connolly J, et al. (2000) Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation. Cancer Res 60: 4139-4145.
24. Tsai J, Lee JT, Wang W, Zhang J, Cho H, et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105: 3041-3046.
25. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
26. Jilaveanu L, Zito C, Lee SJ, Nathanson KL, Camp RL, et al. (2009) Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res 15: 1076-1085.
27. Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340-4346.
28. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, et al. (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135-2147.
29. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, et al. (2008) Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26: 2046-2051.
30. Lutzky J, Bauer J, Bastian BC (2008) Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21: 492-493.
31. Handolias D, Hamilton AL, Salemi R, Tan A, Moodie K, et al. (2010) Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 102: 1219-1223.
32. Karreth FA, DeNicola GM, Winter SP, Tuveson DA (2009) C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Mol Cell 36: 477-486.
33. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464: 431-435.
34. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430.
35. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, et al. (2003) BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 9: 3362-3368.
36. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, et al. (2008) Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 5: e120.
37. Bukur J, Loeffler D, Massa C, Mueller L, Riemann D, et al. (2010) ''Tumor immunology meets oncology IV'', 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany. Cancer Immunol Immunother 59: 955-962.
38. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, et al. (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5: 1136-1144.